Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection

NCT03361956 is registered in ClinicalTrials.gov with Janssen Sciences Ireland UC as lead sponsor.

NCT NCT03361956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03361956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection
Lead sponsor
Janssen Sciences Ireland UC
Phase
Phase 2
Overall status
Completed
Start date
February 13, 2018
Completion date
August 13, 2020
Enrollment
232 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b